Transthyretin Amyloidosis Treatment Market Exclusive Trends Analysis with Forecast to 2031

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Transthyretin Amyloidosis Treatment Market - (By Type (ATTR-PN, ATTR-CM), By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy), By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Transthyretin Amyloidosis Treatment Market is valued at US$ 5.2 billion in 2023, and it is expected to reach US$ 9.4 billion by 2031, with a CAGR of 7.90% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2890

Transthyretin amyloidosis (ATTR amyloidosis) treatment encompasses medical interventions designed to manage and slow the progression of this rare, progressive, and potentially fatal disease caused by the accumulation of abnormal transthyretin protein in tissues and organs. Therapeutic approaches include medications that stabilize or reduce transthyretin production, along with supportive therapies aimed at symptom management and complication prevention.

The growing awareness and improved diagnostic capabilities for identifying rare diseases, including ATTR amyloidosis, are expected to significantly increase the number of diagnosed patients, thereby driving market growth. The expansion of clinical research initiatives focused on developing novel pipeline treatments for transthyretin amyloidosis and related conditions further strengthens market potential.

List of Prominent Players in the Transthyretin Amyloidosis Treatment Market:
• Acrotech Biopharma, LLC
• Alnylam Pharmaceuticals, Inc.
• AstraZeneca PLC
• Astellas Pharma Inc.
• BridgeBio Pharma, Inc.
• Bristol-Myers Squibb Company
• Ionis Pharmaceuticals, Inc.
• Johnson & Johnson
• Prothena Biosciences Limited
• Pfizer Inc.
• SOM Innovation Biotech, S.L.
• Abbvie, Inc.
• Sanofi
• Eidos Therapeutics, Inc
• BELLUS Health Inc

Market Dynamics:
Drivers-
The rising prevalence of transthyretin amyloidosis, particularly among the aging population, is a significant factor driving market growth. With the global elderly population projected to reach 1.5 billion, the incidence of ATTR amyloidosis is expected to rise accordingly. According to a report by Prothena, over 400,000 individuals globally are affected by wild-type ATTR amyloidosis (ATTRwt), while approximately 50,000 individuals suffer from hereditary ATTR amyloidosis (hATTR). Research from NCBI highlights that aging is a major risk factor for ATTRwt, with the heart being the primary organ affected. To enhance awareness and early diagnosis, various organizations have launched initiatives aimed at educating healthcare professionals and patients.

Curious About This Latest Version Of The Report? Enquiry Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/2890

Challenges:
A key challenge in the transthyretin amyloidosis treatment market is the limited awareness among healthcare professionals, leading to misdiagnosis and improper treatment. Additionally, the high cost of newly approved medications presents a financial barrier to patient accessibility. For example, a study by Alnylam Pharmaceuticals, Inc. indicates that the annual cost of Patisiran and Inotersen treatments is approximately $450,000 USD, posing affordability concerns for patients and healthcare systems.

Regional Trends:
The North American market is anticipated to hold a dominant share in revenue due to increased diagnosis rates, growing treatment adoption, and expanding prescription volumes. A significant milestone in the region was Health Canada's approval of ONPATTRO, a treatment for hATTR polyneuropathy, which has contributed to greater access to innovative therapies.
Additionally, the Middle East and Africa are witnessing substantial market growth, driven by high unmet medical needs, rising approval rates for novel therapies, and increasing disease prevalence.

Unlock Your GTM Strategy:
https://www.insightaceanalytic.com/customisation/2890

Segmentation of Transthyretin Amyloidosis Treatment Market-
By Type-
• ATTR-PN
• ATTR-CM
By Therapy-
• Targeted Therapy
o Onpattro
o Inotersen
o Vyndaqel/Vyndamax
• Supportive Therapy
• Pipeline Therapy
By Disease Type-
• Hereditary Transthyretin Amyloidosis
o Polyneuropathy
o Cardiomyopathy
o Mixed Type
• Wild Type Amyloidosis
By Distribution Channel-
• Hospital Pharmacies
• Specialty Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Get more information:
https://www.insightaceanalytic.com/report/transthyretin-amyloidosis-treatment-market/2890

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.JPG

Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace

This release was published on openPR.